The filing covers the sale of the clinical stage biotechnology company's common stock, preferred stock, debt securities, warrants and units.
Unless specified in a prospectus supplement, the company plans to use the net proceeds from the sale of securities for general corporate purposes.
Price: 12.89, Change: -0.08, Percent Change: -0.62
|Deutsche Bank Adjusts Northern Trust's Price Target ...|
|Berkshire Hathaway Adds Stake in Occidental Petroleu...|
|Deutsche Bank Downgrades State Street to Hold From B...|
|Wells Fargo Adjusts Fortune Brands Home & Security's...|
|Wells Fargo Adjusts Owens Corning Price Target to $8...|